Datasets of 55 enrollees were deposited in the European Nucleotide Archive (<http://www.ebi.ac.uk/ena/data/view/PRJEB29071>, accession number: PRJEB29071)

Introduction {#sec001}
============

Gastric cancer (GC) is one of the most common cancers and is the third leading cause of cancer mortality worldwide, with an estimated 783,000 deaths in 2018 \[[@pone.0236197.ref001]\]. South Korea has the highest incidence of stomach cancer in the world \[[@pone.0236197.ref001]\]. A positive family history is a well-known risk factor for GC, in addition to male sex, *Helicobacter pylori* infection, smoking, and frequent consumption of salty food and dietary nitrite \[[@pone.0236197.ref002]\]. Most GC cases are sporadic, with approximately 90% developing in communities carrying only an average risk \[[@pone.0236197.ref003], [@pone.0236197.ref004]\]. Hereditary cancer syndromes including hereditary diffuse gastric cancer (HDGC) account for less than 3% of all GC cases \[[@pone.0236197.ref005]\]. The remaining 7% is found in individuals with a positive family history but without a diagnosed inherited cancer syndrome \[[@pone.0236197.ref005]\].

Individuals with affected first-degree relatives (FDRs) have a 2 to 3-fold increased risk for GC \[[@pone.0236197.ref006]\]. The increased risk in affected families is partly attributable to the sharing of similar environmental factors, such as dietary habits or *H*. *pylori* infection. Nevertheless, frequently observed weak association between *H*. *pylori* infection and GC development in affected families \[[@pone.0236197.ref007], [@pone.0236197.ref008]\] suggests a genetic basis for familial aggregation. Given this background, we hypothesized that genetic predisposition may underlie the high occurrence of GC in GC-prone families.

According to literature, several SNPs associated with GC have been identified via candidate gene approach \[[@pone.0236197.ref005], [@pone.0236197.ref009]\] or a genome-wide association study (GWAS) \[[@pone.0236197.ref010], [@pone.0236197.ref011]\]. One of the most well-known is the association of MUC1 with gastric cancer \[[@pone.0236197.ref012]\]. MUC1 belongs to the mucin family and it is located at the apical surface of the mucosal epithelial cells and acts as a protective barrier against exogenous insults. It is hypothesized that MUC1 variants like rs4072037 influence the quantity and the quality of the MUC1 protein and cause difference in barrier function in the stomach with subsequent difference in GC susceptibility between individuals \[[@pone.0236197.ref012]\].

However, studies on such SNPs have yielded inconsistent results, especially in relation to different GC types and ethnicities \[[@pone.0236197.ref010], [@pone.0236197.ref013]--[@pone.0236197.ref015]\]. Moreover, the effect sizes of SNPs resulting from GWAS were generally small, less than 2.0. Recently, novel GC genes that explain small fractions of familial GC have been identified using whole-genome and whole-exome sequencing (WES), including *PALB2*, *BRCA1*, *and CTNNA1* \[[@pone.0236197.ref008], [@pone.0236197.ref016], [@pone.0236197.ref017]\]. Most previous studies on familial clustering of GC have focused on HDGC or diffuse-type GC \[[@pone.0236197.ref008], [@pone.0236197.ref016]\], although a considerable proportion of intestinal-type GC occurs in GC family clusters \[[@pone.0236197.ref007], [@pone.0236197.ref018]\]. WES studies on GC are rare in Asia, where the prevalence of intestinal-type GC is high.

The objective of this study was to identify GC-associated germline variants with a high effect size \[[@pone.0236197.ref019]\] by linkage and association analyses based on WES of subjects with familial clustering of GC not limited to HDGC. We recruited both affected and unaffected family members and identified *MUC4* as a candidate predisposition gene with a large effect size. We further validated in large populations of cases and controls and through expression analysis of *MUC4* in normal gastric mucosa and gastric cancer tissues.

Materials and methods {#sec002}
=====================

Patient inclusion for exome sequencing {#sec003}
--------------------------------------

From April 2017 to March 2018, GC patients and their FDRs, among families with two or more members diagnosed with GC within three generations, were enrolled in the study at Seoul National University Bundang Hospital. Non-GC controls were defined as individuals aged \> 50 years with a normal endoscopy within the previous 6 months. For diagnosis of GC, it was based on pathologic diagnosis by endoscopic biopsy or surgical specimens.

Family history of GC, smoking, consumption of alcohol, dietary preference, socioeconomic status, gastrointestinal symptoms and a history of previous *H*. *pylori* eradication were acquired via questionnaires. Histologic evaluations with Giemsa staining and an anti-*H*. *pylori* test were performed to determine *H*. *pylori* infection status \[[@pone.0236197.ref007], [@pone.0236197.ref014]\] (online [S1 Table](#pone.0236197.s005){ref-type="supplementary-material"}).

All procedures involving human participants were performed in accordance with the ethical standards of the institutional and national research committees and the 1964 Helsinki Declaration. This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (B-1610-366-303). Members of all families who participated in the present study signed a specific informed consent form.

DNA isolation and whole-exome sequencing {#sec004}
----------------------------------------

Genomic DNA was isolated using the Qiagen DNeasy blood and tissue kit(Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. To perform WES, Agilent SureSelect All Exon V6(Agilent Technologies, Santa Clara, CA) with reagents was used with sequencing libraries and capture. Sequencing was performed on an Illumina HiSeq 2500 platform (2x100 bp-paired end; Illumina, Inc., San Diego, CA). Sequence datasets of the 55 enrollees were deposited in the European Nucleotide Archive ([http://www.ebi.ac.uk/ena/data/view](http://www.ebi.ac.uk/ena/data/view/PRJEB29071)) under accession number PRJEB29071.

Variant detection and annotation {#sec005}
--------------------------------

Raw sequencing reads were aligned to the Human Genome Reference Assembly GRCh37/hg19 using Burrows-Wheeler Aligner(BWA v0.7.15) software \[[@pone.0236197.ref020]\]. The BWA alignment files were converted to BAM files using SAM tools v1.3, and duplicates were marked with Picard (<https://sourceforge.net/projects/picard>, v1.96). Local realignment, base quality recalibration, and haplotype calling in genomic Variant Call Format (gVCF) mode for each sample were performed using the Genome Analysis Toolkit (GATK v3.5) according to best practices \[[@pone.0236197.ref021]\]. Genomic VCF(gVCF) files were combined and joint genotyped with GATK. Functional annotation of genetic variants was conducted using ANNOVAR with population frequencies. Variants on Exon 24 of *MUC4* gene were confirmed by Sanger sequencing and all variant reads were inspected with Integrative Genomes Viewer \[[@pone.0236197.ref022]\].

Linkage and association analyses {#sec006}
--------------------------------

Disease susceptibility loci were identified using linkage analysis and the gene-based association test with Pedigree Variant Annotation, Analysis, and Search Tool (pVAAST) under the autosomal dominant inheritance model and the maximally allowable prevalence of disease, 0.005 \[[@pone.0236197.ref023]\]. The p values of the LOD (logarithm of odds) scores and a gene-based burden-type composite likelihood ratio test (CLRT) for binomial likelihood based on allele counts in cases and controls weighted by functional prediction were calculated from 10^6^ permuted samples using a gene-drop method. At linkage analysis, we compared variants in 19 affected cases to their unaffected 36 controls in all 14 families considering respective family structures. At the gene-based association test we compared allele counts in whole exomes of 19 GC patients to those of 397 Korean control whole genomes obtained from the National Biobank of Korea, Korea National Institute of Health. A total of 19,491 genes were analyzed, and the Bonferroni-adjusted 0.05 level was 2.57×10^−6^. For *MUC4*, 10^8^ permuted samples were used as p value of CLRT score was below 1.0×10^−6^ in 10^6^ permuted samples.

Allele frequency determination {#sec007}
------------------------------

The gnomAD database (<http://gnomad.broadinstitute.org/>) was used to obtain the frequency of specific variants in overall and East Asian control populations.

The Cancer Genome Atlas (TCGA) data analysis {#sec008}
--------------------------------------------

TCGA data were downloaded from the Institute for Systems Biology Cancer Genomics Cloud from the Genome Data Commons legacy (GRCh37/hg19) archive and Genome Data Commons Data Portal ([https://portal.gdc.cancer.gov](https://portal.gdc.cancer.gov/)). Sequence information was obtained from the database of Genotypes and Phenotypes (dbGaP).

Genome-wide association of variants located in *MUC4* {#sec009}
-----------------------------------------------------

Blood samples were collected from 597 histologically confirmed GC patients and 9,758 non-GC subjects who were examined at the Seoul National University Bundang Hospital and the Seoul National University Hospital Healthcare System Gangnam Center. They were genotyped by the Affymetrix Axiom Korean Chip, which consists of 827,783 variants. Any subjects were removed if 1) sex estimated by their genome was different from their clinical information, 2) call rates of subjects were less than 97%, 3) heterozygosity rates deviated by three times their standard deviation from their mean and 4) their identity-by-descent estimates with other subjects were larger than 0.185 and they had higher missing rates than their paired subjects did. Variants were removed whose 1) missing rates were larger than 3% or were significantly different between the case and control groups (p \< 1×10^−5^), 2) minor allele frequencies were smaller than 5% and 3) *P* values for the Hardy-Weinberg equilibrium exact test were smaller than 0.001 as suggested by Anderson *et al*. \[[@pone.0236197.ref024]\]. Then, untyped variants were imputed using the Michigan Imputation Server \[[@pone.0236197.ref025]\]. After imputation, 4,224 variants located in *MUC4* and its 0.5 MB flanking region were analyzed using logistic regression with adjusting for the effects of sex, age, and top 10 principal components of the sample relationship matrix. The Bonferroni-adjusted 0.05 significance level became 1.18×10^−5^. PLINK(v1.90b4.5) and R (v3.5.2) were used for the process \[[@pone.0236197.ref026]\].

Immunohistochemistry (IHC) analyses of noncancerous gastric mucosa and gastric cancer tissue {#sec010}
--------------------------------------------------------------------------------------------

Antral noncancerous mucosa was evaluated using IHC from 15 GC patients and 8 non-GC participants who consented to endoscopic biopsy. In the case of GC patients, cancer tissue was also stained. The antibody for detecting MUC4 (clone: 8G7) (1:100 dilution, Zeta Corporation, Arcadia, CA, USA) was used for IHC. The antibody we have used for IHC detects MUC4α region. The specificity of the antibody was evidenced by previous studies. Overall staining of sections (4 μm thick) was conducted via the BenchMark XT Staining system and ultraVIEW Universal DAB Detection Kit (Ventana Medical Systems, Inc., Tucson, AZ, USA). MUC4 expression was evaluated using light microscopy via multiplication of the intensity by area (%), where staining was observed in the epithelial glands (0 to 300):0, no staining;1+, faint/barely perceptible partial staining; 2+, weak to moderate staining; 3+, strong staining. In cancerous tissue, only strongly stained area loci were included for scoring. Each sample was scored in a blinded manner by a single pathologist (HSL).

MUC4 structural computational analysis {#sec011}
--------------------------------------

Motif search and prediction of peptide cleavage, glycosylation, and protein structure were performed for the analysis of MUC4 structure using the protein sequence (refSeqID:NP_001191215) and mRNA sequence (refSeqID:NM_018406.6), obtained from the NCBI Reference Sequence Database \[[@pone.0236197.ref027]\], as references. A motif search was performed using the MotifFinder tool in GenomeNet([https://www.genome.jp](https://www.genome.jp/); [S1 Fig](#pone.0236197.s001){ref-type="supplementary-material"}). Peptide cleavage prediction was performed using PeptideCutter \[[@pone.0236197.ref028]\] on the MUC4 α region of the protein reference sequences (NP_001191215) and variant sequences. NetOGlyc \[[@pone.0236197.ref029]\] and NetNGlyc (<http://www.cbs.dtu.dk/services/NetNGlyc/>) were used to predict likely locations of O-GalNAc (N-acetylgalactosamine) and N-GalNAc modifications, respectively. Protein structure predictions using homology modeling of MODELLER \[[@pone.0236197.ref030], [@pone.0236197.ref031]\] and SWISS-MODEL were performed but failed to yield reliable structures at the SNV locus.

Effect size analysis {#sec012}
--------------------

The odds ratio (OR) for all significant genes at the Bonferroni-adjusted 0.05 significance level was estimated with logistic regression. Familial correlations were estimated with GMMAT \[[@pone.0236197.ref032]\], and the variance for the random effect that explains familial correlation was estimated to be 0. Thus, GC status among family members was assumed to be independent, and standard logistic regression was applied using *Rex Version 2*.*1* ([http://rexsoft.org](http://rexsoft.org/)). For each gene, genetic risk scores were coded as 1 if one or more rare alleles in the corresponding gene were observed and 0 otherwise. Sex, age, smoking status and HDGC were included as covariates to adjust for their effects.

Results {#sec013}
=======

Characteristics of participants {#sec014}
-------------------------------

The total subjects included 55 participants (19 GC patients and 36 non-GC relatives) from 14 independent families (online [S1 Table](#pone.0236197.s005){ref-type="supplementary-material"}). Pedigrees of the 14 families are presented in [Fig 1](#pone.0236197.g001){ref-type="fig"}. Three HDGC families (Nos. 7, 8 and 13) that met the International Gastric Cancer Linkage Consortium 2010 clinical criteria were included \[[@pone.0236197.ref033]\]. Clinical characteristics of the participants are presented ([Table 1](#pone.0236197.t001){ref-type="table"}; online [S1 Table](#pone.0236197.s005){ref-type="supplementary-material"}).

![Pedigrees of families with *MUC4* variants.\
Participants whose DNA was analyzed in the present study were given a number beginning with "\#." The age at diagnosis of GC is described in parentheses after GC. The arrow indicates a proband. The cross represents death. *mut* denotes a carrier of the variants of genes. \*\#34 has another *MUC4* variant, c.5005A\>G; p.S1669G. GC, gastric cancer (unknown Lauren classification); IGC, intestinal-type gastric cancer; DGC, diffuse-type gastric cancer; RCC, renal cell cancer; ca, cancer; TA, tubule adenoma; F, family.](pone.0236197.g001){#pone.0236197.g001}

10.1371/journal.pone.0236197.t001

###### Clinical and demographic characteristics of GC patients and non-GC subjects.

![](pone.0236197.t001){#pone.0236197.t001g}

  Variables                                             Non-GC (*n* = 36)   GC (*n* = 19)   *P*-value[^a^](#t001fn004){ref-type="table-fn"}
  ----------------------------------------------------- ------------------- --------------- -------------------------------------------------
  Male                                                  12 (33.3)           12 (63.2)       **0.034**
  Age (years)                                           62.14 (9.1)         59.11 (13.8)    0.331
  *MUC1* (rs4072037)                                                                        
   GG                                                   0                   2 (10.5)        0.098
   AG                                                   5 (13.9)            1 (5.3)         
   AA                                                   31 (86.1)           16 (84.2)       
  Rural residence                                       21 (58.3)           14 (73.7)       0.260
  Smoking                                               10 (27.8)           12 (63.2)       **0.011**
  Alcohol consumption                                   22 (61.1)           14 (73.7)       0.351
  Fruit intake ≥3/week                                  26 (72.2)           16 (84.2)       0.320
  *H*. *pylori*                                         27 (75.0)           11 (57.9)       0.192
  Blood-type with B alleles                             11 (30.6)           6 (31.6)        0.938
  *MUC4* variants                                       3 (8.3)             14 (73.7)       **\<0.001**
  Histology of cancer                                                                       
   Intestinal type                                                          13 (63.2)       
   Diffuse type[^c^](#t001fn006){ref-type="table-fn"}                       4(26.3)         
   Unknown                                                                  2 (10.5)        
  HDGC[^d^](#t001fn007){ref-type="table-fn"}                                3 (15.8)        

Most values are shown as numbers (%) except for age which is expressed as a mean (standard deviation).

Bold font indicates statistical significance.

Abbreviations: GC, gastric cancer; HDGC, hereditary diffuse gastric cancer syndrome.

^a^ Statistical significance was determined by the chi-squared test or t-test.

^b^ Based on Lauren classification.

^c^ Including 1 mixed type.

^d^ Families with 2 or more cases of gastric cancer with at least 1 diffuse gastric cancer diagnosed before the age of 50 years old.

The mean age at GC diagnosis was 59.0 years (range: 31--84 years), while that of unaffected relatives was 62 years. A higher percentage of males tended to be present in the GC group than in the other group (63.2% vs. 33.3%, *p* = 0.034). A higher proportion of GC patients experienced smoking than participants in the non-GC group (63.2% vs. 27.8%, *p* = 0.011). Approximately half of GC patients were *H*. *pylori*-positive, while 75.0% of unaffected relatives were *H*. *pylori*-positive without significant differences in these proportions. Among the enrolled GC patients, 3 cases were recognized as diffuse-type, 13 cases as intestinal-type, and one case as mixed-type based on Lauren's classification. The specific histologic type of the remaining cases could not be identified even though we requested this information from the hospitals where the patients were treated mainly due to gastric surgery or histology having been performed a long time ago.

Discovery of germline exome variants associated with gastric cancer {#sec015}
-------------------------------------------------------------------

WES data were generated from the 55 subjects with a mean depth of 96-fold on targeted exome regions (online [S2 Table](#pone.0236197.s006){ref-type="supplementary-material"}). An average of 97% of all targeted regions were covered by at least 20-fold. To explore rare variant candidates for GC, linkage analyses combined with an association test were conducted. Based on LOD *p* values, *MUC4*, *MAGEC1*, and *RETSAT* were identified as putative genes associated with GC ([Fig 2A](#pone.0236197.g002){ref-type="fig"} to [2C](#pone.0236197.g002){ref-type="fig"}). At gene-based CLRT analyses that integrate linkage information, case-control association and functional variant prediction, and *MUC4* reached the genome-wide significance level (*p* value ≤ 9.9×10^−9^, and the genome-wide Bonferroni-adjusted 0.05 significance level = 2.6×10^−6^) ([Fig 2A](#pone.0236197.g002){ref-type="fig"}). [Fig 2B and 2C](#pone.0236197.g002){ref-type="fig"} show the Manhattan and quantile-quantile (QQ) plots for our linkage analyses, respectively, and they show that our statistical analyses preserve the nominal significance level. [S2 Fig](#pone.0236197.s002){ref-type="supplementary-material"} shows the QQ plots for LOD *p* values of three different gene size groups, and they confirm that our analyses are not affected by gene size.

![Candidate predisposition genes for gastric cancer by combined linkage analyses with pVAAST.\
(A) Predisposition genes that were detected are described. A composite likelihood ratio test (CLRT) based on the binomial likelihood for allele counts in cases and controls weighted by the functional prediction likelihood ratio was conducted with 10^6^ permuted samples by the gene drop method. (B) Manhattan plot of the logarithm of odds (LOD) *p* values of all protein-encoding genes from the pVAAST run; each dot in the plot represents a *p* value for one gene. The x-axis shows the genomic locations arranged by chromosome. (C) quantile-quantile (QQ) plot of the LOD *p* values from pVAAST.](pone.0236197.g002){#pone.0236197.g002}

*MUC4* variants {#sec016}
---------------

When the full dataset was analyzed using pVAAST, 14 variants of *MUC4* were found to contribute to the LOD score, and 10 of these were finally selected with LOD values greater than 0. The 10 variants of *MUC4* were identified among 14 independent families ([Table 2](#pone.0236197.t002){ref-type="table"}). All subjects who harbored these variants were affected by GC except for cases \#16, \#37 and \#39 ([Table 2](#pone.0236197.t002){ref-type="table"}). GC patients with *MUC4* variants mostly had intestinal-type GC except \#23 ([Fig 1](#pone.0236197.g001){ref-type="fig"}). The three unaffected participants (\#16, \#37 and \#39) were all female and nonsmokers. Two variants, namely, c.7658C\>T p.A2553V and c.5005A\>G p.S1669G, were identified in three unrelated families. Participants \#15, \#16, \#19, \#34 and \#51 carried two different variants each. Most of the variants identification rates in populations of East Asian origin were higher than those observed in the overall population ([Table 2](#pone.0236197.t002){ref-type="table"}).

10.1371/journal.pone.0236197.t002

###### Characteristics of the germline *MUC4* variants associated with gastric cancer by linkage analysis in the 14 studied families.

![](pone.0236197.t002){#pone.0236197.t002g}

  Location[^a^](#t002fn001){ref-type="table-fn"}   Allelic change    AA change   LOD            Affected case   Population MAF                                     Exon           Functional prediction   
  ------------------------------------------------ ----------------- ----------- -------------- --------------- -------------------------------------------------- -------------- ----------------------- -----------------
  chr3:195513076                                   C                 T           p.Arg1792His   0.60            **[51]{.ul}**, **[52]{.ul}**, **[53]{.ul}**        0.044/ 0.433   2                       O-glycosylation
  rs774527434                                      (Alpha subunit)                                                                                                                                        
  chr3:195513446                                   T                 C           p.Ser1669Gly   1.20            **[34]{.ul}, [2]{.ul}, [30]{.ul}**                 0.262/ 1.460   2                       O-glycosylation
  rs534579185                                      (Alpha subunit)                                                                                                                                        
  chr3:195510793                                   G                 A           p.Ala2553Val   1.57            **[11]{.ul}**, **[19]{.ul}**, **[23]{.ul}**        0.062/ 0.028   2                       O-glycosylation
  rs77250903                                       (Alpha subunit)                                                                                                                                        
  chr3:195507271                                   G                 C           p.Thr3727Ser   0.90            **[51]{.ul}**                                      0.017/ 0.226   2                       O-glycosylation
  rs868067409                                      (Alpha subunit)                                                                                                                                        
  chr3:195475923                                   G                 A           p.Thr5295Met   0.60            **[34,]{.ul}**[37]{.ul}**[, 38,]{.ul}**[39]{.ul}   0.001/ 0.011   24                      N-glycosylation
  rs531395109                                      (Beta subunit)                                                                                                                                         
  chr3:195507778                                   G                 A           p.Ala3558Val   0.35            **[5]{.ul}**                                       0.016/ 0.000   2                       O-glycosylation
  rs754808151                                      (Alpha subunit)                                                                                                                                        
  chr3:195512387                                   G                 A           p.Leu2022Phe   0.30            **[32]{.ul}**[,]{.ul}**[33]{.ul}**                 0.001/ 0.009   2                       O-glycosylation
  rs1304612772                                     (Alpha subunit)                                                                                                                                        
  chr3:195510803                                   G                 T           p.Pro2550Thr   0.30            **[19]{.ul}**                                      0.008/ 0.000   2                       O-glycosylation
  rs774907241                                      (Alpha subunit)                                                                                                                                        
  chr3:195511813                                   C                 T           p.Ser2213Asn   0.14            **[15]{.ul}**[, 16]{.ul}                           0.001/ 0.009   2                       O-glycosylation
  rs771925912                                      (Alpha subunit)                                                                                                                                        
  chr3:195511811                                   G                 T           p.Pro2214Thr   0.04            **[15]{.ul}**[, 16]{.ul}                           0.000/ 0.000   2                       O-glycosylation
  rs745342765                                      (Alpha subunit)                                                                                                                                        

^a^ Chromosome position in reference genome, GRCh37/hg19.

^b^ ID of subjects diagnosed with gastric cancer is highlighted in a bold style and case numbers with an underline belong to the same family.

^c^ MAF (%) in overall and East Asian population from gnomAD (v2.1) exome database.

Effect size of *MUC4* variants in the development of gastric cancer {#sec017}
-------------------------------------------------------------------

Standard logistic regression was applied to all 55 family members with adjustments for sex, tobacco smoking, and HDGC (see methods). Carrying any *MUC4* variation was associated with an increased risk of GC (*MUC4*; OR 58.08, 95% CI 7.33 to 459.97; online [S3 Table](#pone.0236197.s007){ref-type="supplementary-material"}).

Validating the association of *MUC4* with gastric cancer in large case control cohort {#sec018}
-------------------------------------------------------------------------------------

As we hypothesized that hereditary and sporadic gastric cancer may share genetic background for gastric cancer, we further analyzed whether variants of *MUC4* are related to the development of GC in a large cohort which consists of 597 GC patients and 9759 healthy controls genotyped with SNP array. Common SNPs of *MUC4* regions (chr3: 195,473,637--195,539,149), including 0.5 MB of flanking region, were analyzed, and the Bonferroni-adjusted 0.05 significance level was 1.18×10^−5^. Two common variants in *MUC4* lesions (rs148735556 and rs11717039) were detected ([S3 Fig](#pone.0236197.s003){ref-type="supplementary-material"}), suggesting the association of *MUC4* with GC. In exon 2 and 24 regions of *MUC4*, there were 25 SNPs, and the rs547775645 missense variant in exon 2 was identified to be significant at the 0.05/25 = 2×10^−3^ significance level. The imputation quality of the above mentioned ten rare variants in *MUC4* was poor (INFO \< 0.5), and they could not be tested in this SNP chip analysis. However, the presence of common variants in *MUC4* with significant association with GC supports that germline *MUC4* variants might be linked with GC.

Frequency of *MUC4* germline variants in patients with multiple cancer types {#sec019}
----------------------------------------------------------------------------

We investigated the allele frequency of MUC4 variants in germline samples of patients with multiple cancer types because MUC4 is highly expressed not only in stomach but also other tissues such as colon, esophagus, small intestine, uterus, and lung and patients with germline MUC4 variants might be at higher risk of developing multiple types of cancers. We tested whether the 10 rare variants of *MUC4* gene were related to cancer using germline variants from blood in the Cancer Genome Atlas Study data. We identified three rare variants in *MUC4* associated with gastric cancer and 4 other cancer types (online [S4 Table](#pone.0236197.s008){ref-type="supplementary-material"}). Out of 10 associated variants of the *MUC4* gene that have been linked to familial GC in [Table 2](#pone.0236197.t002){ref-type="table"}, a heterozygote rs774527434 SNP was identified in one (0.17%) patient among 295 stomach adenocarcinoma germline samples (online [S4 Table](#pone.0236197.s008){ref-type="supplementary-material"}), approximately 4 times higher than that in the general population (0.04%, [Table 2](#pone.0236197.t002){ref-type="table"}). Two variants, rs534779185 and rs77250903, were identified in 372 CRC patients, with frequencies of 4.0% and 0.13%, respectively, higher than that in the general population (0.26 and 0.06% respectively, [Table 2](#pone.0236197.t002){ref-type="table"}). One variant, rs534779185, was found in 265 uterine corpus endometrial cancer samples with a frequency of 0.56%. It is interesting that none of the ten variants of the *MUC4* gene were identified in 408 lung squamous cell cancer or 495 lung adenocarcinoma patients, suggesting that *MUC4* variants might be related with gastrointestinal or genitourinary tract cancers.

*MUC4* expression in stomach tissues of subjects with *MUC4* variants {#sec020}
---------------------------------------------------------------------

To investigate the functional effects of the identified variants, *MUC4* expression in gastric mucosa was measured using IHC. Representative immunohistochemical results of 5 participants in family No. 14 which showed complete cosegregation with *MUC4* variants (rs774527434) and contained the largest number of gastric cancer patients are shown ([Fig 3](#pone.0236197.g003){ref-type="fig"}). While *MUC4* variant-negative, noncancerous mucosa (\#50, \#54) ([Fig 3A and 3D](#pone.0236197.g003){ref-type="fig"}) displayed high intensities, the IHC results of *MUC4* variant-positive noncancerous mucosa from three patients (\#51, \#52 and \#53; [Fig 3B, 3E and 3H](#pone.0236197.g003){ref-type="fig"}) with *MUC4* variants were weak or negative. In contrast, the cancer tissues of three patients (\#51, \#52 and \#53; [Fig 3C](#pone.0236197.g003){ref-type="fig"}, [3F and 3I](#pone.0236197.g003){ref-type="fig"}) showed high IHC scores.

![Representative photomicrographs of IHC for *MUC4* in noncancerous and cancerous gastric mucosal tissue of Family No. 14 (original magnification A-F, H, and I ×400). Panel A is tissue of \#50 (participant number); B & C \#51; D, \#54; E & F, \#52; H & I, \#53. Intensive staining (brown) of *MUC4* in noncancerous tissue (A, D) in the representative *MUC4* variant-negative control is shown compared to absent or faint immunoreactivity of noncancerous tissue in *MUC4* variant-positive gastric cancer patients (B, E & H). The paired cancer tissue (C, F and I) of B, E and H show intense and diffuse staining of *MUC4*. G, *MUC4* immunointensity in *MUC4* variant-positive noncancerous mucosa was weaker than that in the *MUC4* variant-negative (left). Despite an increased tendency of immunointensity in *MUC4* variant-positive cancer tissue, no statistical significance was observed (right). The white bar represents *MUC4* variant-negative, while the black bars denote *MUC4* variant-positive.](pone.0236197.g003){#pone.0236197.g003}

Generally, noncancerous mucosa with *MUC4* variants exhibited a lower score of *MUC4*-positive staining than those with wild type ([Fig 3G](#pone.0236197.g003){ref-type="fig"}; median \[interquartile range\]: 0 \[10.0--30.0\] vs. 70 \[9.5--165.0\], *p* = 0.023). In cancer tissue, there was a tendency towards more prominent IHC staining in those with *MUC4* variants compared to the wild type ([Fig 3G](#pone.0236197.g003){ref-type="fig"}; median \[interquartile range\]: (75.0 (0--240.0) vs. 30 (0--105.0), *p* = 0.287)

Prediction of protein structure {#sec021}
-------------------------------

Nine of the 10 *MUC4* variants identified in the present study were located in exon 2, which includes a tandem repeat region \[[@pone.0236197.ref034]\], while the other variant existed in exon 24. Neither homology modeling nor ab initio structural modeling was successful due to the absence of established *MUC1* or *MUC4* models and the coil structure of the O-glycosylation-rich site.

According to the prediction for glycosylation \[[@pone.0236197.ref029], [@pone.0236197.ref035]\], most *MUC4* variants in exon 2 were O-glycosylation sites or physically close to them (online [S5 Table](#pone.0236197.s009){ref-type="supplementary-material"}). In particular, p.T3727S, p.S1669G and p.S2213N were more likely to carry O-GalNAc modifications \[[@pone.0236197.ref029]\]. Change in a single codon from G to A (c.5375G\>A:p.R1792H) of this putative cleavage site may potentially inhibit proteolytic activity. The change in a single codon from C to T (c.15884C\>T) hampered the synthesis of threonine, a prospective N-glycosylation site between the second and third epidermal growth factor (EGF)-like domains of the *MUC4* ß subunit ([S4 Fig](#pone.0236197.s004){ref-type="supplementary-material"}).

Discussion {#sec022}
==========

To identify novel GC-susceptible genes, we performed WES in 19 GC-affected members and 36 unaffected FDRs of 14 families in which 2 or more GC cases had occurred within the third generation. Linkage and association analyses identified *MUC4* missense variants as a predisposition to the familial aggregation of GC. The discovery of common variants in *MUC4* region significantly linked with gastric cancer in a large case control cohort of gastric cancer supports the association of *MUC4* with gastric cancer. Downregulated IHC results in normal gastric mucosa of *MUC4* variant carriers were found relative to wild type, suggesting the loss of protective function of *MUC4* in carriers of *MUC4* variants.

Unlike previous studies that recruited only hereditary diffuse gastric cancers, we invited families with more than two members with gastric cancer regardless of pathologic subtypes as our focus was to uncover GC susceptibility variants related to familial clustering. We invited both affected and unaffected family members but it was very difficult to recruit relatives because some had already died from gastric cancer and others were reluctant to be taken blood or consent to genetic study. The practical difficulty in recruiting participants may be one factor that hampers the genetic study of cancers with familial clustering.

*MUC4* is a large, heavily glycosylated transmembrane mucin, varying from 550 to 930 kDa, due to the polymorphic variable number tandem repeat region \[[@pone.0236197.ref034]\]. It is expressed in the normal epithelium of several organs, including the stomach, intestine and mammary glands, and protects and lubricates the epithelium \[[@pone.0236197.ref034]\]. *MUC4* shares structural similarities with *MUC1* but also possesses unique regions, including three EGF-like domains, which are required for activation of ErbB2.

While the association *MUC1* and gastric carcinogenesis is relatively well documented \[[@pone.0236197.ref012]\], knowledge concerning the role of *MUC4* in gastric carcinogenesis is limited. Normal *MUC1* blocks adhesion of *H*. *pylori* to the gastric mucosa, thus preventing *H*. *pylori* colonization \[[@pone.0236197.ref036]\] and gastritis \[[@pone.0236197.ref037]\]. However, there was no significant interaction between H. pylori status and *MUC4* variants in the development of GC in our study. It might be due to the small sample size of the study cohort but a study with larger sample size that compared the clinical factors between GC patients with or without family history of GC suggested that the effect of H. pylori infection on GC development decreases among GC patients with family history of GC \[[@pone.0236197.ref007]\]. Two recent meta-analysis studies have shown that the G allele of *MUC1* rs4072037 is associated with a decreased risk of GC \[[@pone.0236197.ref038], [@pone.0236197.ref039]\]. *MUC1* rs4072037 affects the gene promoter, leading to reduced transcriptional activity and *MUC1* \[[@pone.0236197.ref040], [@pone.0236197.ref041]\].

In the present study, we attempted to explain the possible mechanism of the association between *MUC4* variant and GC risk through expression analyses of *MUC4*. Although only a limited number of gastric mucosal samples could be obtained, we found that *MUC4*-stained cells tended to decrease in the noncancerous gastric mucosa. As *MUC4* is structurally similar to *MUC1* and as carriers of *MUC4* variants displayed decreased expression of *MUC4*, we hypothesized that *MUC4* variants cause a detrimental effect by preventing the expression of *MUC4* in normal mucosa. This trend was most prominent among family members with c.5375G\>A:p.R1792H of *MUC4* (Family No. 14) ([Fig 3](#pone.0236197.g003){ref-type="fig"}).

The structures of either MUC1 or MUC4 have not been experimentally confirmed to date. To characterize the molecular nature of *MUC4* where variants affect, we tried to predict protein structure. MUC4 contains 5412 amino acid residues. Among them, 4264 amino acid residues from the N-terminus are predicted to be an intrinsically disordered region (IDR) by the XtalPred server \[[@pone.0236197.ref042]\] that plays physiological roles through nonstructured domains \[[@pone.0236197.ref043]\]. Our attempts to model the exon 2 region of MUC4, where many variants are located, were unsuccessful because the N-terminal IDR of MUC4 does not contain templates for modeling.

Nevertheless, the information we obtained from *in silico* prediction of glycosylation in MUC4 structure indicates that most regions encoded by *MUC4* variants are likely to be O-glycosylation sites. O-glycosylation with glycan micro-heterogeneity is crucial to mucin structure and function. Mucin-type glycans are involved in specific ligand-receptor interactions and can confer hydroscopic properties and bind various small molecules and proteins, finally stabilizing the protein structure \[[@pone.0236197.ref044]\]. Although hundreds of O-glycosylation sites exist in the MUC4α subunit, a different amino acid on one specific site may lead to altered functioning of the encoded variant protein \[[@pone.0236197.ref045]\]. Positional preference for amino acids \[[@pone.0236197.ref046]\] and changes in serine or threonine \[[@pone.0236197.ref034]\] around the O-glycosylation site in the present study provide the basis of altered glycosylation of MUC4.

While mucins play an essential role in forming a protective barrier over various tissues under normal physiological conditions, abnormal *MUC4* expression has been reported in certain types of carcinomas, including those of the lung, breast, pancreas, and stomach \[[@pone.0236197.ref034]\]. The IHC findings of the present study confirm those of previous studies that reported increased *MUC4* expression in cancer tissue compared to normal tissue ([Fig 3](#pone.0236197.g003){ref-type="fig"}). The excessive expression of *MUC4* in cancer tissue could reflect a dual role as an oncogene. Previous studies suggested that *MUC4* may activate the ErbB2 oncoprotein during the pathogenesis of GC \[[@pone.0236197.ref047], [@pone.0236197.ref048]\]. In addition, the variant in exon 24, p.Thr5295Met, might be involved in ErbB2 signaling because the variant causes an amino acid change in an N-glycosylation site between the EGF-like domains ([S4 Fig](#pone.0236197.s004){ref-type="supplementary-material"}). The structural model of a putative third EGF-like domain of MUC4 we managed to obtain covers residues from F5300 to L5362, which is in close proximity to variant residue T5295M. Because this site is only five residues away from the modeled EGF-like domain, it is plausible that this variant may affect the function of the EGF-like domain ([S4 Fig](#pone.0236197.s004){ref-type="supplementary-material"}).

The frequencies of the *MUC1* rs4072037 A allele in our study cohort of 90.9% were comparable to those in 1,124 Chinese GC patients (97.2%) \[[@pone.0236197.ref049]\], while those of the A and G alleles were 57.9% and 42.1% in American populations and 49.2% and 50.8% in African populations, respectively \[[@pone.0236197.ref050]\]. These results indicate that East Asian populations may be genetically susceptible to GC through *MUC1* variants. The frequencies of most identified *MUC4* variants in the present study were generally higher in the East Asian population than those observed in the global population, including those of western origin ([Table 2](#pone.0236197.t002){ref-type="table"}). Moreover, One variant of *MUC4* (rs774527434) was identified in Asian GC patient in TCGA. Overall, putative *MUC4* variants in this study may contribute to geographic differences in GC incidence parallel to *MUC1* variant.

As GC has a heterogeneous etiology, individuals in the GC family could exhibit a discrepancy between genetic susceptibility and clinical presentation. In the present study, 5 GC patients without *MUC4* variants were identified among 4 independent families: \#20, \#28, \#43, \#45, and \#46 ([Fig 1](#pone.0236197.g001){ref-type="fig"}). Diffuse-type GC patient \#28, who met the HDGC criteria, harbored novel missense mutations in *CDH1* (NM_001317184: exon8:c.G1057A:p.E353K). Although family \#46 met the HDGC criteria, no mutation in *CDH1* or *CTNNA1* was found \[[@pone.0236197.ref017], [@pone.0236197.ref051]\]. Patients \#43 and \#45 belonged to the same family with two renal cell cancers, suggesting the possibility of other genetic syndromes. Notably, the association of *MUC4* variants with GC development may be strong in non-HDGC and mostly intestinal-type GC in the Korean population.

The present study did not conduct functional analyses for *MUC4*. Nonetheless, the strength of the present study is that a family-based linkage analysis was designed in a familial clustering setting. The presence of affected and unaffected members in a family allowed for the selection of variants whose phenotypes segregated on a per-family basis. We provided external validation data with SNP chip analysis in large case control cohort of GC. We also included intestinal-type GC, while many studies on familial GC have shown that genetic predisposition correlated with diffuse-type GC only.

The limitations of our study are that the sample size was small and we could not experimentally demonstrate the functional significance of MUC4 variants. And we could not adjust for confounders or examine the difference in demographic characteristics as the whole genome dataset of 379 Koreans from the National Biobank of Korea do not contain phenotype data and we did not investigate genomic structural variations such as large copy number variations. Also, we could not investigate the association of MUC4 variants with disease severity as some of the patients with gastric cancer were treated at other hospitals and clinical data about disease severity like tumor staging and survival were not available.
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Reviewer \#1: Reviewer's comment on "Family-based exome sequencing combined with linkage analyses identifies rare susceptibility variants of MUC4 for gastric cancer" (PONE-D-20-15912) authored by Choi et al.

This study aimed to identify germline variants predisposing for gastric cancer by using linkage analysis and association analysis. Authors conducted whole exome sequencing based on DNA from blood samples of 19 gastric cancer patients and 36 unaffected family members from 14 families. The result of their linkage analysis identified MUC4 as a predisposing gene for gastric cancer. A further genetic association analysis based on 597 gastric cancer patients and 9,759 normal controls suggested three SNPs on MUC4 associated with gastric cancer. Immunohistochemistry experiment suggested the loss of protective function of MUC4 for the carriers of germline missense mutations in MUC4. In general, the paper is well written and the results are informative.

Abstract. "And the MUC4 variants were found in higher frequency in The Cancer Genome Atlas Study (TCGA) germline samples of patients with multiple cancer types." Is it not clear why authors would like to examine the rare variants of MUC4 in other cancers in TCGA? In addition, when the allele frequency was compared, did authors consider the difference in allele frequency for the individuals with different ethnic background? In the comparison, the variant data were all from blood samples or from different tissue types? In addition, on page 19, the description "One variant of MUG ..." seems not informative and cannot support the statement in abstract. The materials related to TCGA may be removed from this study.

Materials and method. Authors compared allele counts in whole exome of 19 gastric cancer patients to those of 397 Korean control from National Biobank of Korea. The clinical and demographic characteristics were similar? Potential confounders were adjusted for in the comparison?

Authors are suggested to examine structural variation at least for MUC4 in gastric cancer patients and healthy controls.

Reviewer \#2: Minor comments:

In the present study (PONE-D-20-15912) the authors explored to identify novel gastric cancer (GC)-susceptible genes and performed whole-exome sequencing (WES) in 19 GC-affected members and 36 unaffected FDRs of 14 families in which 2 or more GC cases had occurred within the third generation. Linkage and association analyses identified MUC4 missense variants as a predisposition to the familial aggregation of GC. Although, this is a large and well-designed case-control study and authors have performed extensive tools to discover common variants in MUC4 region which are significantly linked with GC, I have following minor comments regarding the study:

1\. Sample size calculation for patients with GC and control is not mentioned. For calculation of sample size, which software was used and specify the test used. How the power of the study was calculated? Also, please mention how the effect size of SNPs was analyzed?

2\. Inclusion and exclusion criteria for the participants should be mentioned clearly. For example, how the healthy subjects were recruited? Did they fill out questionnaires on gastrointestinal symptoms? For a diagnosis of GC, was it based on one or a combination of clinical, radiological, and endoscopic criteria?

3\. Is the genotype frequency in MUC4 gene differ in any particular age group?

4\. H. pylori status in co-relation with MUC4 variant might have some roles in pathogenesis of GC. The results section lacks association between GC with or without MUC4 variant and H. pylori status. Also, some discussion on this point needs to be included.

5\. In the introduction section, it should be mentioned on the role of MUC on host physiology, and how mutant variant might affect in the pathogenesis. The roles of MUC4 can only be speculative at this moment without any functional studies.

6\. Please mention the clinical history of patients with anti-microbial therapy, H2-receptor blockers etc. were excluded from this study? This will make the study for better presentation.

7\. How the variant MUC4 is associated with GC disease severity?

8\. Did the authors observe any association of MUC1, and MUC4 variants in a same GC patient? As MUC1variant and gastric carcinogenesis is well documented.

9\. What are the study limitations? Addition of a paragraph on this would be better.

10\. Though the host\'s genetic factors play an important role in gastric carcinogenesis, the role of diet cannot be denied. History of dietary habit might add some novel finding in relation with MUC4 variant.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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18 Jun 2020

Dear Editor-in-Chief:

RE: PONE-D-20-15912

Family-based exome sequencing combined with linkage analyses identifies rare susceptibility variants of MUC4 for gastric cancer

coauthored by Yoon Jin Choi, Jung Hun Ohn, Sung Ho Won, Won Ji Kim, Kyungtaek Park, Lee Sael, Cheol Min Shin, Sun Min Lee, Sejoon Lee, Hyun Joo An, Dong Man Jang, Byung Woo Han, Hye Seung Lee, Seung Joo Kang, Joo Sung Kim and Dong Ho Lee.

Thank you very much for giving us the opportunity for revision. Accurate and kind comments by the reviewer have been addressed in the revised manuscript. We also believe that these comments improved our manuscript. Major changes have been highlighted in Red color in the revised manuscript, and revised supplementary table 1 to avoid any confusion.

I anticipate good response.

Thank you!

Sincerely,

Nayoung Kim, M.D.

Reviewer \#1:

Reviewer's comment on "Family-based exome sequencing combined with linkage analyses identifies rare susceptibility variants of MUC4 for gastric cancer" (PONE-D-20-15912) authored by Choi et al.

This study aimed to identify germline variants predisposing for gastric cancer by using linkage analysis and association analysis. Authors conducted whole exome sequencing based on DNA from blood samples of 19 gastric cancer patients and 36 unaffected family members from 14 families. The result of their linkage analysis identified MUC4 as a predisposing gene for gastric cancer. A further genetic association analysis based on 597 gastric cancer patients and 9,759 normal controls suggested three SNPs on MUC4 associated with gastric cancer. Immunohistochemistry experiment suggested the loss of protective function of MUC4 for the carriers of germline missense mutations in MUC4. In general, the paper is well written and the results are informative.

Abstract. "And the MUC4variants were found in higher frequency in The Cancer Genome Atlas Study (TCGA) germline samples of patients with multiple cancer types." Is it not clear why authors would like to examine the rare variants of MUC4 in other cancers in TCGA?

Response\>

Thank you very much for the comment. We investigated the allele frequency of MUC4 variants in germline samples of multiple cancer types because MUC4 is highly expressed not only in stomach but also other tissues such as colon, esophagus, small intestine, uterus, and lung (<https://www.proteinatlas.org/ENSG00000145113-MUC4/tissue>) and patients with germline MUC4 variants might be at higher risk of developing cancers in those tissues. Following the reviewer's comment, we added the following sentence to explain why we examined the allele frequency of MUC4 variants in multiple cancer types.

Results section page 14 lines 20-23\>

"We investigated the allele frequency of MUC4 variants in germline samples of patients with multiple cancer types because MUC4 is highly expressed not only in stomach but also other tissues such as colon, esophagus, small intestine, uterus, and lung and patients with germline MUC4 variants might be at higher risk of developing multiple types of cancers."

In addition, when the allele frequency was compared, did authors consider the difference in allele frequency for the individuals with different ethnic background?

Response\>

We really appreciate the reviewer's comment. Unfortunately, we could not take into the difference in allele frequency with different ethnic background as only 3% of TCGA patients are Asians as reported by Spratt DE et al. (JAMA Oncol. 2016 Aug 1;2(8):1070-4.) Therefore, we had to compare the allele frequency to that in the general population.

In the comparison, the variant data were all from blood samples or from different tissue types?

Response\>

The variant data were all from blood samples. We specified that the variant data were from blood samples in the results section as following:

Page 14, line 24\>

"We tested whether the 10 rare variants of MUC4 gene were related to cancer using germline variants from blood in the Cancer Genome Atlas Study data"

In addition, on page 19, the description "One variant of MUC4 ..." seems not informative and cannot support the statement in abstract. The materials related to TCGA may be removed from this study.

Response\>

We appreciate the specific suggestion. As suggested by the reviewer, we removed the TCGA related sentence from the abstract. But we did not totally remove the TCGA part as we thought that the analysis may be informative because MUC4 is highly expressed not only in stomach but also other tissues such as colon, esophagus, small intestine, uterus, and lung (<https://www.proteinatlas.org/ENSG00000145113-MUC4/tissue>) and patients with germline MUC4 variants might be at higher risk of developing cancers in those tissues.

Materials and method. Authors compared allele counts in whole exome of 19 gastric cancer patients to those of 397 Korean control from National Biobank of Korea. The clinical and demographic characteristics were similar? Potential confounders were adjusted for in the comparison?

Response\>

We are thankful for the comment. As the whole genome dataset of 379 Koreans from the National Biobank of Korea do not contain phenotype data, we could not adjust for confounders or examine the difference in demographic characteristics. We added the point in the limitation section of the discussion.

Page 20, lines 1-3 \>

"The limitations of our study are that ... And we could not adjust for confounders or examine the difference in demographic characteristics as the whole genome dataset of 379 Koreans from the National Biobank of Korea do not contain phenotype data ..."

Authors are suggested to examine structural variation at least for MUC4 in gastric cancer patients and healthy controls.

Response\>

We really appreciate the suggestion. Calling structural variation such as copy number deletions from exome sequencing dataset is limited although tools like EXCAVATOR are available. We plan to investigate exome-wide structural variation from our whole exome dataset of gastric cancer families in a separate study and added it in limitation section of the discussion.

Page 20 lines 3-4\>

"The limitations of our study are that ... and we did not examine structural variations such as large copy number variations."

The authors really appreciate the reviewer's kind and accurate comments. The revision based on these comments made this manuscript more accurate and the quality improved. Thank you.

Nayoung Kim, M.D., Ph.D.

 

Reviewer \#2: Minor comments:

In the present study (PONE-D-20-15912) the authors explored to identify novel gastric cancer (GC)-susceptible genes and performed whole-exome sequencing (WES) in 19 GC-affected members and 36 unaffected FDRs of 14 families in which 2 or more GC cases had occurred within the third generation. Linkage and association analyses identified MUC4 missense variants as a predisposition to the familial aggregation of GC. Although, this is a large and well-designed case-control study and authors have performed extensive tools to discover common variants in MUC4 region which are significantly linked with GC, I have following minor comments regarding the study:

1\. Sample size calculation for patients with GC and control is not mentioned. For calculation of sample size, which software was used and specify the test used. How the power of the study was calculated? Also, please mention how the effect size of SNPs was analyzed?

Response\>

We appreciate the comment. We did not calculate sample size before the study design. As we mentioned in the second paragraph of the discussion section, it is very difficult to recruit relatives because some had already died from gastric cancer and others were reluctant to be taken blood or consent to genetic study. The practical difficulty in recruiting participants may be one factor that hampers the genetic study of cancers with familial clustering. At first we recruited 10 families with familial clustering of gastric cancer, and we found significant signal in MUC4 variants. We tried to validate the result by recruiting 4 additional families and the result was consistent.

We described how the effect size of MUC4 SNPs was calculated in page 9 of methods section as following:

Page 9, lines 16-23\>

"The odds ratio (OR) for all significant genes at the Bonferroni-adjusted 0.05 significance level was estimated with logistic regression. Familial correlations were estimated with GMMAT, and the variance for the random effect that explains familial correlation was estimated to be 0. Thus, GC status among family members was assumed to be independent, and standard logistic regression was applied using Rex Version 2.1 (<http://rexsoft.org>). For each gene, genetic risk scores were coded as 1 if one or more rare alleles in the corresponding gene were observed and 0 otherwise. Sex, age, smoking status and HDGC were included as covariates to adjust for their effects."

2\. Inclusion and exclusion criteria for the participants should be mentioned clearly. For example, how the healthy subjects were recruited? Did they fill out questionnaires on gastrointestinal symptoms? For a diagnosis of GC, was it based on one or a combination of clinical, radiological, and endoscopic criteria?

Response\>

We are very thankful for the specific comment. Subjects in families with two or more members diagnosed with GC within three generations were asked to fill out questionnaires about family history of GC, smoking, consumption of alcohol, dietary preference, socioeconomic status, a history of previous H. pylori eradication and gastrointestinal symptoms. Healthy subjects were defined as individuals aged \> 50 years with a normal endoscopy within the previous 6 months. For diagnosis of GC, it was based on pathologic diagnosis by endoscopic biopsy or surgical specimens. We added it in methods section page 6 line 6-9,

"From April 2017 to March 2018, GC patients and their FDRs, among families with two or more members diagnosed with GC within three generations, were enrolled in the study at Seoul National University Bundang Hospital. Non-GC controls were defined as individuals aged \> 50 years with a normal endoscopy within the previous 6 months. For diagnosis of GC, it was based on pathologic diagnosis by endoscopic biopsy or surgical specimens.

Family history of GC, smoking, consumption of alcohol, dietary preference, socioeconomic status, gastrointestinal symptoms and a history of previous H. pylori eradication were acquired via questionnaires. Histologic evaluations with Giemsa staining and an anti-H. pylori test were performed to determine H. pylori infection status."

3\. Is the genotype frequency in MUC4 gene different in any particular age group?

Response\>

We thank the reviewer for the specific comment. There was no difference in genotype frequency in MUC4 in age groups. And the mean age of subjects with MUC4 variants versus subjects without MUC4 variants were not significantly different (63.7 years vs. 60.0 years, p=0.209).

4\. H. pylori status in co-relation with MUC4 variant might have some roles in pathogenesis of GC. The results section lacks association between GC with or without MUC4 variant and H. pylori status. Also, some discussion on this point needs to be included.

Response\>

We appreciate the comment. There was no significant interaction between H. pylori status and MUC4 variants in the development of GC. It might be associated with the small sample size but in a study with large sample size that compared the clinical factors between GC patients with or without family history of GC suggest that the effect of H. pylori infection on GC development decreases among GC patients with family history of GC. (Medicine (Baltimore) 2016 May;95(20):e3606). We added the point in the discussion section page 17, lines 22-26.

"However, there was no significant interaction between H. pylori status and MUC4 variants in the development of GC in our study. It might be due to the small sample size of the study cohort but a study with larger sample size that compared the clinical factors between GC patients with or without family history of GC suggested that the effect of H. pylori infection on GC development decreases among GC patients with family history of GC\[7\]."

5\. In the introduction section, it should be mentioned on the role of MUC on host physiology, and how mutant variant might affect in the pathogenesis. The roles of MUC4 can only be speculative at this moment without any functional studies.

Response\>

We really appreciate the comment. With respect to MUC1 which belongs to the mucin family, it is located at the apical surface of the mucosal epithelial cells and acts as a protective barrier against exogenous insults. It is hypothesized that MUC1 variants like rs4072037 influence the quantity and the quality of the MUC1 protein and cause difference in barrier function in the stomach with subsequent difference in GC susceptibility between individuals (Int J Mol Sci. 2014 May 7;15(5):7958-73). We added the point in the introduction section of the revised manuscript page 4 lines 17-22,

"One of the most well-known is the association of MUC1 with gastric cancer \[12\]. MUC1 belongs to the mucin family and it is located at the apical surface of the mucosal epithelial cells and acts as a protective barrier against exogenous insults. It is hypothesized that MUC1 variants like rs4072037 influence the quantity and the quality of the MUC1 protein and cause difference in barrier function in the stomach with subsequent difference in GC susceptibility between individuals \[12\]."

6\. Please mention the clinical history of patients with anti-microbial therapy, H2-receptor blockers etc. were excluded from this study? This will make the study for better presentation.

Response\>

We appreciate the comment. Even though H. pylori was treated, authors thought that past infections could still affect the gastric carcinogenesis in some degree. In addition, there are many cases that do not have exact information about the anti-H. pylori therapy and the entire study subjects are small, authors could not do stratification analysis. We will conduct next research, taking into account the reviewer\'s comments.

A summary of whether H. pylori eradicated was described in supplementary table S1 with the new Erad column. Thank you!

7\. How the variant MUC4 is associated with GC disease severity?

Response\>

We are thankful for the comment of the reviewer. Unfortunately, we could not investigate the association of MUC4 variants with disease severity as some of the patients with gastric cancer were treated at other hospitals and clinical data about disease severity like tumor staging and survival were not available. We added the point in the limitation paragraph of the revised manuscript page 20 lines lines 4-6.

" ... Also, we could not investigate the association of MUC4 variants with disease severity as some of the patients with gastric cancer were treated at other hospitals and clinical data about disease severity like tumor staging and survival were not available."

8\. Did the authors observe any association of MUC1, and MUC4 variants in a same GC patient? As MUC1variant and gastric carcinogenesis is well documented.

Response\>

We did not observe the association between MUC1 and MUC4 variants in the same GC patient. It may be because the well-documented "A" allele of the MUC1 variant rs4072037, that increases the risk of gastric cancer, was very common in our study cohort (the allele frequency was as high as 90.9% in our study cohort as described in the Discussion section page 19 line 16).

9\. What are the study limitations? Addition of a paragraph on this would be better.

Response\>

We appreciate the helpful comment of the reviewer. We added a paragraph on the study limitations in the revised manuscript, page 19 line 28 to page 20 line 6,

"The limitations of our study are that the sample size was small and we could not experimentally demonstrate the functional significance of MUC4 variants. And we could not adjust for confounders or examine the difference in demographic characteristics as the whole genome dataset of 379 Koreans from the National Biobank of Korea do not contain phenotype data and we did not investigate genomic structural variations such as large copy number variations. Also, we could not investigate the association of MUC4 variants with disease severity as some of the patients with gastric cancer were treated at other hospitals and clinical data about disease severity like tumor staging and survival were not available."

10\. Though the host\'s genetic factors play an important role in gastric carcinogenesis, the role of diet cannot be denied. History of dietary habit might add some novel finding in relation with MUC4 variant.

Response\>

Thank you very much for the suggestion. In our previous study, which included a cohort with large sample size, the intra-familial aggregation of gastric cancer was associated with environmental factors such as diet shared during childhood (Eur J Gastroenterol Hepatol. 2011;23:411-7) However, there was no significant association between dietary factors and gastric cancer in our study subjects, which might be because of the small sample size of the current study.

The authors really appreciate the reviewer's kind and accurate comments. The revision based on these comments made this manuscript more accurate and the quality improved. Thank you.

Nayoung Kim, M.D., Ph.D.

10.1371/journal.pone.0236197.r003
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